Skip to main content

Clara Carnicer Cáceres

Institutions of which they are part

Postdoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Clara Carnicer Cáceres

Institutions of which they are part

Postdoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Projects

Caracterización clínica de variantes patogénicas e investigación de nuevos factores pronósticos en la nefropatía IgA

IP: -
Collaborators: Manuel Hernández González, David Beneitez Pastor, Clara Carnicer Cáceres, Maria Teresa Salcedo Allende
Funding agency: Instituto de Salud Carlos III
Funding: 90750
Reference: PI10/01055
Duration: 01/01/2011 - 31/12/2013

Related news

The project aims to improve prevention, diagnosis, and treatment through computational biomedicine, innovative therapies, and the transfer of knowledge into clinical practice.

The annual event offered a space for dialogue between the scientific community and society on how to address the future of ageing through research and innovation.

Docetaxel, carried by Soluplus, proved to be the most effective and least toxic combination to cross the blood-brain barrier and attack the tumour directly.

Related professionals

Ruben Fernández Galera

Ruben Fernández Galera

Postdoctoral researcher
Cardiovascular Diseases
Read more
Alba Estela García Fernández

Alba Estela García Fernández

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Nataly Reyes Calderon

Nataly Reyes Calderon

Predoctoral researcher
General Surgery
Read more
Daniel Alvarez De la Sierra

Daniel Alvarez De la Sierra

Research technician
Translational Immunology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.